ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1977

The Proangiogenic Function of the Epigenetic Regulator EZH2 in Synovial Tissue Is Mediated By Fibroblasts in Rheumatoid Arthritis

Michelle Trenkmann1, Steffen Gay2, Douglas J. Veale1 and Ursula Fearon1, 1Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, 2Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Angiogenesis, epigenetics and fibroblasts

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose

The histone methyltransferase Enhancer of Zeste 2 (EZH2) is overexpressed in solid tumors and is associated with invasion, malignancy and tumor angiogenesis. EZH2 expression is upregulated in rheumatoid arthritis (RA) synovial fibroblasts (SF) whose activated phenotype drives them to invade and destroy articular cartilage.  Another hallmark of the inflamed rheumatoid joint is angiogenesis and RASF are important regulators of this pathway secreting proangiogenic molecules and providing a molecular scaffold for blood vessel formation.  Here, we studied the role of EZH2 in the interplay of RASF and endothelial cells in RA.

Methods

Fresh biopsies of synovial tissue (ST) from RA patients were stimulated with tumor necrosis factor alpha (TNFα, 10ng/ml) for 24h (explant culture) and RNA was isolated (n=3). Human microvascular endothelial cells (HMVEC) were stimulated with proinflammatory stimuli, Toll-like receptor (TLR) ligands or synovial fluid (2%, 5% and 10%) for different periods of time (n=3). RASF (n=4) were transfected with siRNA targeting EZH2. After 72h and 96h, cells were analyzed for EZH2, interleukin (IL)-6, IL8 and vascular endothelial growth factor (VEGF) expression at mRNA (by quantitative real-time PCR) and protein levels (by ELISA). 

Results

Ex vivo, TNFα induced the expression of EZH2 in RA ST (1.8±0.3-fold) which was accompanied by an increase in the expression and copious secretion of proinflammatory and proangiogenic mediators, namely IL6 (from 77±88 ng/ml to 197±163 ng/ml) and IL8 (from 105±53 ng/ml to 220±30 ng/ml). Since RA ST explant cultures maintain the synovial architecture with cell-cell and cell-matrix contacts thus mimicking the in vivo situation, these data indicate that chronic inflammation within the RA synovium upregulates EZH2 expression in vivo. Our previous work demonstrated that TNFα upregulates EZH2 in RASF. Silencing of EZH2 in RASF changed the expression and secretion of IL6 and VEGF into cell culture supernatants whereas no significant changes were observed for IL8. Specifically, IL6 and VEGF were downregulated by EZH2 knockdown both under basal (by 39±17% and 29±8%) and TNFα-stimulated (by 30±18% and 38±6%) conditions which was confirmed at the protein level by ELISA. To elucidate whether other cell types show the same EZH2 expression pattern, HMVEC were studied for their response to pathogenetically relevant stimuli. No significant changes in EZH2 expression, however, were observed following proinflammatory stimuli (TNFα, IL-1β, IL-17), TLR stimulation (TLR2, 3 and 4) or treatment with synovial fluid, ruling out a direct effect of inflammation-induced EZH2 on endothelial cell behaviour.

Conclusion

Here we show that TNFα induces the expression of the epigenetic regulator EZH2 in RA ST explants ex vivo. In vitro, TNFα regulates EZH2 expression in RASF but not in endothelial cells. Silencing of EZH2 in RASF decreased the expression and secretion of IL6 and VEGF. These data imply that induction of EZH2 by TNFα in synovial tissue and RASF drives proinflammatory and proangiogenic mechanisms in RASF.


Disclosure:

M. Trenkmann,
None;

S. Gay,
None;

D. J. Veale,

Abbvie,

2,

MSD,

2,

Pfizer Inc,

2,

Roche ,

2,

Pfizer ,

5,

Roche ,

5,

Abbott,

8,

MSD,

8,

Pfizer,

8,

Roche ,

8;

U. Fearon,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-proangiogenic-function-of-the-epigenetic-regulator-ezh2-in-synovial-tissue-is-mediated-by-fibroblasts-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology